Author information from the last article
Avdeling for blodsykdommer
Oslo universitetssykehus
og
Institutt for klinisk medisin
Universitetet i Oslo
Forfatterbidrag: ide, fortolking av datamaterialet, utarbeiding/revisjon av selve manuset og godkjenning av innsendte manusversjon.
Tobias Gedde-Dahl er seksjonsleder og førsteamanuensis.
Articles by Tobias Gedde-Dahl
Allogeneic stem cell transplantation for acute myeloid leukaemia 2005–22
- Kari Busterud,
- Mats Remberger,
- Pål Tore Bentsen,
- Marianne Brenn Jerm,
- Tobias Gedde-Dahl,
- Astrid M. Olsnes,
- Geir E. Tjønnfjord
08.10.2025:
Each year, 150 to 200 people are diagnosed with acute myeloid leukaemia (AML) in Norway (1). Most patients receiving curative treatment achieve complete remission with intensive chemotherapy, but many relapse if chemotherapy is the only treatment given (2, 3). Allogeneic stem cell transplantation...
Allogeneic stem cell transplantation for patients with lymphoma 2011–21
- Hege Melby Frøen,
- Marianne Brodtkorb,
- Harald Holte,
- Arne Kolstad,
- Anders Eivind Myhre,
- Mats Remberger,
- Geir Erland Tjønnfjord,
- Tobias Gedde-Dahl
03.03.2025:
Allogeneic stem cell transplantation (ASCT) is potentially curative for patients with haematologic malignancies, lymphomas and certain non-malignant conditions. However, it carries a risk of severe complications and transplant-related mortality due to organ damage, infection and graft-versus-host...
Allogeneic stem cell transplantation in adults 2015–21
- Camilla Dao Vo,
- Anders Eivind Myhre,
- Ingerid Weum Abrahamsen,
- Mats Remberger,
- Jonas Mattsson,
- Yngvar Fløisand,
- Bjørn Christer Linder Grønvold,
- Geir Erland Tjønnfjord,
- Tor Henrik Anderson Tvedt,
- Tobias Gedde-Dahl
14.03.2023:
Allogeneic stem cell transplantation is the only curative treatment for a number of malignant haematological diseases and congenital or acquired immunodeficiencies. In allogeneic stem cell transplantation, the patient's own bone marrow is destroyed following pre-transplant treatment with high-dose...